ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Reduce Drug Realization Time

27-May-2008

ThalesNano Inc. and sanofi-aventis R&D announced the signing of a research and development collaboration agreement focusing on continuous process chemistry technologies.The collaboration will focus on the development and implementation of continuous process technologies from research to full-scale production. The purpose of the project is to study the utilization and application of ThalesNano's integrated continuous process chemistry technologies within the sanofi-aventis drug R&D process from discovery to API production.

"We are delighted to work with sanofi-aventis R&D who have always been at the forefront of applying new methods and technologies to improve the drug discovery and development process," said Dr. Laszlo Urge, CEO of ThalesNano Inc. "The ThalesNano continuous process technology is already well established in the discovery labs of the life sciences industry. Taking it to process scale promises tremendous benefits for our customers in terms of reducing development time, increasing cost efficiency and minimizing environmental impact."

Other news from the department research and development

Most read news

More news from our other portals

Discover the latest developments in battery technology!